GlassScriptPhysician profile
Marion K W Ho
NPI 1003929225
$3,261.33
in general payments reported to CMS, 2019-2025
25 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $434 · 2021: $776 · 2022: $384 · 2023: $378 · 2024: $52.07 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $490.45 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Janssen Pharmaceuticals, INC | $439.77 | 2019-2021 | |
| Novo Nordisk INC | $406.22 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.49 | 2019-2023 | Jardiance, Trijardy Xr, Tradjenta |
| Abbvie INC. | $333.22 | 2019-2023 | |
| Amgen INC. | $332.39 | 2019-2025 | Evenity, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $166.20 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $138.75 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $97.67 | 2019-2021 | |
| Mannkind Corporation | $92.21 | 2019-2022 | |
| Amarin Pharma, INC. | $56.57 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $47.84 | 2019-2023 | Contrave |
| Allergan, INC. | $46.97 | 2019-2021 | |
| Vivus LLC | $42.78 | 2019-2020 | |
| Dexcom, INC. | $28.11 | 2023 | Dexcom G6 Transmitter |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $26.45 | 2019 | |
| Medtronic Minimed, INC. | $25.40 | 2019 | |
| Lucid Diagnostics INC. | $22.86 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $20.90 | 2021 | |
| Glaxosmithkline, LLC. | $19.18 | 2020 | |
| Indivior INC. | $18.24 | 2021 | |
| Tandem Diabetes Care, INC. | $16.65 | 2020 | |
| Gilead Sciences, INC. | $15.96 | 2022 | |
| Bausch Health US, LLC | $15.89 | 2020 | |
| Abbott Laboratories | $15.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marion Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.